Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 18;14(3):416-422.
doi: 10.18240/ijo.2021.03.14. eCollection 2021.

Real-world outcomes of two-year Conbercept therapy for diabetic macular edema

Yong Cheng  1   2   3 , Li Yuan  1   2   3 , Ming-Wei Zhao  1   2   3 , Tong Qian  1   2   3
Affiliations

Real-world outcomes of two-year Conbercept therapy for diabetic macular edema

Yong Cheng et al. Int J Ophthalmol. .

Erratum in

  • CORRIGENDUM.
    [No authors listed] [No authors listed] Int J Ophthalmol. 2021 Apr 18;14(4):581. eCollection 2021. Int J Ophthalmol. 2021. PMID: 33875951 Free PMC article.

Abstract

Aim: To evaluate the two-year outcomes of patients treated for diabetic macular edema (DME) with intravitreal Conbercept (IVC).

Methods: The clinical data of 30 DME patients (36 eyes) were retrospectively reviewed. The patients were treated with IVC for 3mo. Additional IVC was given at subsequent monthly visits, if needed (3+PRN). The patients were followed up for 24mo.

Results: The best-corrected visual acuity (BCVA) at 24mo significantly increased (66.7±15.3 letters) in comparison with the baseline (54.4±15.4 letters, P<0.0001). The mean improvement in BCVA was 11.0±2.9 letters. At 24mo, 44.1% of the eyes surveyed gained ≥15 letters, 52.9% of the eyes gained ≥10 letters, and 70.6% of the eyes gained ≥5 letters. No vision loss was noted in 96.8% of the eyes, and 5.9% of the eyes lost ≥5 letters, but ≤10 letters. The central retinal thickness (CRT) at 24mo was significantly reduced (277.1±122.9 µm) in comparison with the baseline (510.9±186.1 µm, P<0.0001). At 24mo, 43.3% of the patients had a CRT ≤250 µm. The mean number of injections over 24mo was 10.6±2.0. No severe eye or systemic adverse events related to either the drug or injection were noted.

Conclusion: IVC is safe and effective for the treatment of DME.

Keywords: Conbercept; diabetic macular edema; intravitreal; visual acuity.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The mean change of BCVA in comparison with baseline during 24mo.
Figure 2
Figure 2. The percentage of gained or lost letters in comparison with baseline during 24mo.
Figure 3
Figure 3. The mean reduction in CRT in comparison with baseline during 24mo.
Figure 4
Figure 4. Fundus status of a patient with proliferative diabetic retinopathy before and after Conbercept treatment
A: Fundus status before treatment; B: Fundus fluorescein angiography images before treatment; C: OCT examination images before treatment; D: OCT images after three successive Conbercept treatments; E: OCT images after 12 consecutive Conbercept treatments.
Figure 5
Figure 5. Fundus status of a patient with nonproliferative diabetic retinopathy before and after Conbercept treatment
A: Fundus status before treatment; B: Fundus fluorescein angiography images before treatment; C: OCT examination images before treatment; D: OCT images after three successive Conbercept treatments; E; OCT images after eight successive Conbercept treatments.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besançon S, Bommer C, Esteghamati A, Ogurtsova K, Zhang P, Colagiuri S. Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020;162:108072. - PubMed
    1. Mori K, Yoshida S, Kobayashi Y, Ishikawa K, Nakao S, Hisatomi T, Haruta M, Isihibashi T, Sonoda KH. Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms. Graefes Arch Clin Exp Ophthalmol. 2020;258(4):735–741. - PubMed
    1. Rasti R, Allingham MJ, Mettu PS, Kavusi S, Govind K, Cousins SW, Farsiu S. Deep learning-based single-shot prediction of differential effects of anti-VEGF treatment in patients with diabetic macular edema. Biomed Opt Express. 2020;11(2):1139–1152. - PMC - PubMed
    1. Whitehead M, Wickremasinghe S, Osborne A, Van Wijngaarden P, Martin KR. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert Opin Biol Ther. 2018;18(12):1257–1270. - PMC - PubMed
    1. Roy S, Kim D, Sankaramoorthy A. Mitochondrial structural changes in the pathogenesis of diabetic retinopathy. J Clin Med. 2019;8(9):1363. - PMC - PubMed

LinkOut - more resources